Transfusion and Apheresis Science
Volume 42, Issue 2 , Pages 141-150 , April 2010

Lymphoma – Emerging realities in sub-Saharan Africa

  • Gerhard Sissolak

      Affiliations

    • Division of Clinical Haematology – Department of Internal Medicine, Faculty of Health Sciences, Stellenbosch University, South Africa
    • The Department of Haematology and Bone Marrow Transplant Unit, The Searll Research Laboratory for Cellular and Molecular Biology, Constantiaberg Medi-Clinic, Burnham Road, Plumstead, Cape Town, South Africa
    • ,
  • June Juritz

      Affiliations

    • University of Cape Town, South Africa
    • ,
  • Dagmar Sissolak

      Affiliations

    • Division of Community Health, Faculty of Health Sciences, University of Stellenbosch, South Africa
    • ,
  • Lucille Wood

      Affiliations

    • Division of Clinical Haematology – Department of Internal Medicine, Faculty of Health Sciences, Stellenbosch University, South Africa
    • The Department of Haematology and Bone Marrow Transplant Unit, The Searll Research Laboratory for Cellular and Molecular Biology, Constantiaberg Medi-Clinic, Burnham Road, Plumstead, Cape Town, South Africa
    • ,
  • Peter Jacobs

      Affiliations

    • Division of Clinical Haematology – Department of Internal Medicine, Faculty of Health Sciences, Stellenbosch University, South Africa
    • University of Cape Town, South Africa
    • College of Medicine, University of Nebraska Medical Centre, United States
    • The Department of Haematology and Bone Marrow Transplant Unit, The Searll Research Laboratory for Cellular and Molecular Biology, Constantiaberg Medi-Clinic, Burnham Road, Plumstead, Cape Town, South Africa
    • Corresponding Author InformationCorresponding author. Address: Constantiaberg Medi-Clinic, P.O. Box 294, Plumstead 7800, Cape Town, South Africa. Tel.: +27 21 799 2566; fax: +27 21 761 4278.

References 

  1. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. The international harmonization project on lymphoma. J Clin Oncol. 2007;25:579–586
  2. Armitage JO, Bierman PJ, Bociek RG, Vose JM. Lymphoma 2006: classification and treatment. Oncology. 2006;20:231–239
  3. Centkowski P, Sawczuk-Chabin J, Prochorec M, Warzocha K. Hodgkin’s lymphoma and tuberculosis coexistence in cervical lymph nodes. Leuk Lymphoma. 2005;46:471–475
  4. Sissolak G, Abayomi EA, Jacobs P. AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART): an African perspective. Transfus Apher Sci. 2007;37:63–70
  5. Nathwani BN, Sasu SJ, Ahsanuddin AN, Hernandez AM, Drachenberg MR. The critical role of histology in an era of genomics and proteomics: a commentary and reflection. Adv Anat Pathol. 2007;14:375–400
  6. Margalit O, Somech R, Amariglio N, Rechavi G. Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications. Blood Rev. 2005;19:223–234
  7. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112:4384–4399
  8. Lupescu IG, Grasu M, Goldis G, Popa G, Gheorghe C, Vasilescu C, et al. Computer tomographic evaluation of digestive tract non-Hodgkin’s lymphomas. J Gastrointest Liver Dis. 2007;16:315–319
  9. Nogami M, Nakamoto Y, Sakamoto S, Fukushima K, Okada T, Saga T, et al. Diagnostic performance of CT, PET, side-by-side, and fused image interpretations for restaging of non-Hodgkin lymphoma. Ann Nucl Med. 2007;21:189–196
  10. Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N, Coya J, Rodriguez-Vigil B, Madero R, et al. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol. 2006;135:293–302
  11. Moid F, DePalma L. Comparison of relative value of bone marrow aspirates and bone marrow trephine biopsies in the diagnosis of solid tumor metastasis and Hodgkin lymphoma: institutional experience and literature review. Arch Pathol Lab Med. 2005;129:497–501
  12. Crowther D, Lister TA. The Cotswolds report on the investigation and staging of Hodgkin’s disease. Br J Cancer. 1990;62:551–552
  13. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1994;329:987–94.
  14. Micallef IN, Remstein ED, Ansell SM, Colgan JP, Inwards DJ, Johnston PB, et al. The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leuk Lymphoma. 2006;47:1794–1799
  15. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265
  16. In: 47th annual meeting of the American society of hematology, Atlanta, Georgia, December 2005. Benefit of induction and maintenance rituximab therapy in relapsed/resistant follicular NHL: final results of the EORTC 20981 trial. Clin Lymphoma Myeloma 2006;6:264–5.
  17. Ravandi F, O’Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest. 2006;24:718–725
  18. Schaefer-Cutillo J, Friedberg JW, Fisher RI. Novel concepts in radioimmunotherapy for non-Hodgkin’s lymphoma. Oncology. 2007;12:203–212
  19. Di Bella N, Ravandi F. Purine analogue combinations for indolent lymphomas. Semin Hematol. 2006;43(Suppl. 2):S11–S21
  20. Abayomi EA, Sissolak G, Jacobs P. Use of novel proteasome inhibitors as a therapeutic strategy in lymphomas: current experience and emerging concepts. Transfus Apher Sci. 2007;37:85–92
  21. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, et al. Experience with heat shock protein–peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer. 2007;109:77–83
  22. Jacobs P, Wood L. Lymphoma – the immune system in disarray. Theme for the 11th congress of the South African Lymphoma Study Group meeting. Transfus Apher Sci. 2005;32:21–23
  23. Jacobs P, Wood L, Ruff P. Hodgkin lymphoma in developing countries: an African perspective with a note on Asia and Latin America. In: Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM, editors. Hodgkin lymphoma. 2nd ed. Philadelphia: Williams & Wilkins; 2007. p. 427–48.
  24. Jacobs P. Lymphoma – histopathology in changing clinical perspective. S Afr Med J. 2000;90:135–141
  25. Jacobs P, Wood L, Armitage JO. In: Proceedings of the 12th biennial congress – South African Lymphoma Study Group. Transfus Apher Sci 2007;37:27–9.
  26. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234
  27. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–565
  28. Jacobs P, Wood L. Immunohematopoietic stem cell transplantation: introduction and 35 years of development in South Africa – the historical and scientific perspective. Bone Marrow Transplant. 2008;42(Suppl. 1):S125–S132
  29. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin’s lymphomas. Hematol Oncol. 2005;23:10–17
  30. Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23:8018–8024
  31. Ahmad A, Govil Y, Frank BB. Gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol. 2003;98:975–986
  32. Baldini L, Brugiatelli M, Luminari S, Lombardo M, Merli F, Sacchi S, et al. Treatment of indolent B-cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol. 2003;21:1459–1465
  33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  34. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–220
  35. UNAIDS. 2006 report on the global AIDS epidemic: executive summary. A UNAIDS 10th anniversary special edition. Geneva: UNAIDS; 2006.
  36. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. The non-Hodgkin’s lymphoma classification project. Ann Oncol. 1998;9:717–720
  37. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood 1997;89:3909–18.
  38. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of Anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. The German–Austria–Swiss ALL-BFM Study Group. Blood. 2000;95:3310–3322
  39. Gribben JG. How I treat indolent lymphoma. Blood. 2007;109:4617–4626
  40. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423
  41. Fabbri A, Lenoci M, Gozzetti A, Chitarelli I, Olcese F, Raspadori D, et al. Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol. 2007;139:90–93
  42. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119:976–984
  43. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–3071
  44. van Agthoven M, Sonneveld P, Hagenbeek A, Uyl-de Groot CA. A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin’s lymphoma. Hematol J. 2003;4:399–409
  45. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab–CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127
  46. Haas RLM, Poortmans P, de Jong D, Aleman BMP, Dewit LGH, Verheij M, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474–2480
  47. Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, et al. Treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol. 1998;16:3007–3015
  48. Summerfield GP, Taylor PR, Mounter PJ, Proctor SJ. High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin’s lymphoma. Br J Haematol. 2002;116:781–786
  49. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454–1459
  50. Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993;11:644–651
  51. Van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–3301
  52. Santini G, Nati S, Spriano M, Gallamini A, Pierluigi D, Congiu AM, et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin’s lymphoma. Haematologica. 2001;86:282–286
  53. Dreyling M, Forstpointner R, Gramatzki M, Böck H, Hänel M, Seymour J, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2006;Suppl. 24 [Abstr 7502].
  54. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–122
  55. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006
  56. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732
  57. Montoto S, Moreno C, Domingo-Domenech E, Estany C, Oriol A, Altes A, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica. 2008;93:207–214
  58. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803–3809
  59. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  60. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–633
  61. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for elapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–3688
  62. Mead GM, Sydes MR, Walawski J, Grigg A, Hatton CS, Pescosta N, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:1264–1274
  63. Kong LR, Samuelson E, Rosen ST, Roenigk HH, Tallman MS, Rademaker AW, et al. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. Leuk Lymphoma. 1997;26:89–97
  64. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood. 2006;107:1255–1264
  65. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185–187
  66. Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin’s lymphoma. Haematologica. 2005;90:1680–1692
  67. Sokol L, Loughran TP. Large granular lymphocyte leukemia. Oncologist. 2006;11:263–273
  68. Josting A, Rudolph C, Mapara M, Glossmann JP, Sienawski M, Sieber M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005;16:116–123
  69. Chau I, Watkins D, Cunningham D. Gemcitabine and its combinations in the treatment of malignant lymphoma. Clin Lymphoma. 2002;3:97–104
  70. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002;19(Suppl.):S27–S32
  71. Escalón MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer. 2005;103:2091–2098
  72. Oken MM. MOPP/ABV hybrid chemotherapy for advanced Hodgkin’s disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998;16:19–26
  73. Straus DJ. How I treat mantle cell lymphoma. J Oncol Pract. 2007;3:281–282

PII: S1473-0502(10)00010-8

doi: 10.1016/j.transci.2010.01.009

Transfusion and Apheresis Science
Volume 42, Issue 2 , Pages 141-150 , April 2010

Article Tools

* Image Usage & Resolution